Difficulties conducting research of marijuana treatments (Schedule I category substance) to determine efficacy and safety, support towards research and development of pharmaceutical cannabinoids, suggestions to change to Schedule II substance
Dangers of marijuana to the developing brain, issues that professionals with limited knowledge of chemical content or dosing are prescribing the liquid extract to infants, children and teens, challenges of no randomized clinical trials, recognition of both benefits and drawback of cannabinoids
Dangers of Marijuana to the developing brain, necessity for advocating for product regulations close to those of tobacco and alcohol, strict penalties and restrictions, and child safe packaging
Necessity of early education (effects of marijuana use during pregnancy/around children and adolescents), physical changes in the brain and risks associated with marijuana use, delayed/altered development of fetus/newborns